A point mutation in the Janus tyrosine kinase 2 (JAK2) gene has been described in patients with chronic myeloproliferative disorders (MPD), but the clinical significance of JAK2 V617F , which may be harbored in either the heterozygote or homozyote status, is still largely undefined. There are indirect suggestions that clinical phenotype and also some biological characteristics are dependent on the mutated allele levels. We have designed and validated in 179 MPD patients an amplification-refractory mutation sequencing PCR assay that allows the relative quantitation of mutated and normal JAK2 mRNAs using dyelabelled mutation-specific primers and capillary electrophoresis. Direct sequencing confirmed the specificity of the assay, which has a detection limit D1% and allowed to identify 9% more JAK2-mutated patients as compared to conventional allele-specific PCR. The mutated mRNA ratio ranged from 5 to 51% in the JAK2 V617F heterozygote and from 45 to 100% in the homozygote patients. Expression levels of both PRV-1 and NF-E2 gene, previously found to be overexpressed in MPD patients, were significantly correlated to the amount of mutated JAK2 mRNA. We propose that this method might complement current technologies based on genomic DNA analysis, and lead prospectively to a better clinically oriented assessment of the impact of JAK2 V617F mutation in MPD. Leukemia 
Introduction
The pathogenesis of Philadelphia-negative chronic myeloproliferative disorders (MPD), 1 which include polycythemia vera (PV), essential thrombocythemia (ET) and chronic idiopathic myelofibrosis (IM), is still largely unknown. Unlike chronic myeloid leukemia (CML), where the presence of the t(9;22) Ph 0 chromosome and of the underlying molecular abnormality has been known for decades 2 and ultimately led to the development of target-specific drugs, 3 the molecular lesion(s) at the basis of the other MPD has remained elusive. 4 Only recently an acquired G-T point mutation in exon 12 of the gene encoding the Janus tyrosine kinase 2 (JAK2), leading to a V-F change at position 617 (JAK2 V617F ) in the JH2 pseudo-kinase domain, has been discovered. [5] [6] [7] [8] The mutated JAK2 is a constitutively active tyrosine kinase that confers growth factor independence in transfected hematopoietic cell lines, [6] [7] [8] reminiscent of the erythropoietin (EPO) hypersensitivity found in EPO-independent colonies of most PV patients. 5, 9 Furthermore, in vivo expression of JAK2 V617F in a murine transplant model induced erythrocytosis. 6 Methods for detection of JAK2 V617F mutation based on the analysis of genomic DNA obtained from peripheral blood granulocytes have been devised and already entered the clinical practice. They include direct sequencing, [6] [7] [8] with a detection limit around 25%, and allele-specific (ASO) PCR 5 or amplification-refractory mutation sequencing (ARMS) PCR, 10 which have a detection limit of D3%. The reported frequency of JAK2 V617F mutation is around 80% (range, 65-100%) in PV, 40% (range, 23-57%) in ET and 55% (range, 35-95%) in IM patients.
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JAK2
V617F mutation is found in either the heterozygote or the homozygote status, the latter arising from mitotic recombination; [5] [6] [7] [8] there are significant differences in the incidence of homozygosity, which involves about 30% of patients in PV and IM and less than 4% in ET.
Whether the presence of the mutation itself can help in identifying biologically and/or clinically distinct subgroups of patients is largely unsettled. 16 In fact, in some of the series published until now, the presence of the mutation has been associated with longer disease duration, propensity to myelofibrosis development (in PV or ET patients) or to leukemia transformation, higher risk of thrombotic complications, advanced age or greater requirement for therapy, whereas others have reported the opposite or no correlation at all; 5, 7, 8, 14, 15, 17 also, a poorer overall survival has been reported in JAK2 V617F IM patients. 18 In a large survey on ET patients, the presence of the mutation was associated to clinical and biological features suggestive of a PV-like disease, thus supporting the view that these two disorders represent a biological continuum; 19 furthermore, according to the presence of the JAK2 V617F mutation, ET patients could be divided into two distinct subpopulations characterized by different disease presentation, clinical complications and response to therapy. 19 One of the reasons underlying such discrepancies may be that the genomic end-point techniques employed in those studies did not allow to determine the actual amount of mutated versus wild-type JAK2. On the other hand, there are indications that the clinical phenotype might be dependent on the proportion of mutated allele, as the expression levels of some aberrantly regulated genes in MPD, such as PRV-1 or NF-E2, have been found higher in homozygote than in heterozygote patients. [20] [21] [22] We addressed this issue by developing an ARMS assay on complementary DNA (cDNA) obtained from granulocyte mRNA that, through the use of dye-labelled specific primer sets and capillary electrophoresis, provides a reliable quantitative estimate of the ratio of mutated versus wild-type JAK2 mRNA. The technique is simple, specific and can be easily adopted in the diagnostic workup of MPD patients.
Materials and methods
Patients, granulocyte preparation, DNA and RNA extraction and cDNA synthesis This study included 63 patients with PV and 85 with ET, diagnosed according to the WHO (World Health Organization) criteria, 23 and 31 with IM. Diagnosis of IM was performed according to the Consensus Criteria; 24 all patients had overt fibrotic IM according to the WHO criteria. 25 Blood sampling was performed after an informed consent either at the diagnosis or during the follow-up, but free from chemotherapy. Fourty healthy blood donors were used as controls; 20 subjects with reactive erythrocytosis were analyzed as well.
Granulocytes were separated by differential centrifugation over a Ficoll-Paque gradient, starting from 20 ml peripheral blood collected in ethylenediaminetetraacetic acid, within 2 h from sampling; contaminating red cells were removed by hypotonic lysis, and cell pellets, which contained 498% of granulocytes by visual inspection of cytosmears, were either resuspended in Trizol for RNA extraction or processed for DNA purification using the QIAmp DNA blood Kit (Qiagen, GmbH, Germany). DNA and RNA were quantified with the NanoDrop technology (Wilmington, DE, USA). Complementary DNA was reverse transcribed starting from 1 mg RNA with random hexamers and MuLV reverse transcriptase (Applied Biosystems, Forster City, CA, USA).
Analysis of JAK2
V617F mutation
Search for JAK2 V617F mutation was performed by an ASO PCR, starting from 75 ng granulocyte DNA, exactly as described by Baxter et al. 5 To evaluate whether the mutation was carried in the homozygous or heterozygous state, digestion of PCR products with BsaXI restriction enzyme (New England Biolabs, Hitchin, UK) was performed as described. 5 In a small number of subjects (see below), also the ARMS assay on granulocyte DNA was performed, exactly as described. 10 Amplification Refractory Mutation System for quantitation of JAK2 V617F mutated cDNA
Tetra-primer ARMS-PCR is a procedure originally developed for the analysis of single nucleotide polymorphisms (SNP), which employs two primer pairs to amplify, respectively, the two different alleles of an SNP in a single PCR reaction. 26 Primers were designed according to a public available ARMS design program (http://cedar.genetics.soton.ac.uk/public_html/ primer1.html) and included mismatches at the 3 0 end of ) and in representative patients with heterozygous (Hetero) or homozygous (Homo) JAK2 V617F mutation, as assessed by BsaXI restriction enzyme analysis on granulocyte DNA (negative print of the original ethidium -bromide-stained gel examined under UV). Circled amplicons were extracted from the gel and subjected to sequencing; correct sequence, corresponding to the WT and mutated JAK2, respectively, is shown in the insets on the right.
Quantitative assay for JAK2 V617F RNA AM Vannucchi et al mutation-specific primers to maximize discrimination of the two cDNAs. The two mutation-specific primers were labelled with 5-carboxyfluorescein; primer sequences and their location on target sequence are shown in Figure 1a and b. Amplification was performed for 27 cycles at 621C, with AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA, USA) starting from 50 ng cDNA. Amplified products were resolved in an ABI PRISM 310 analyzer using standard protocols. The percentage of mutated and wild-type alleles was determined by calculating the proportion of the respective, integrated, peak areas as compared to the sum of both peak areas, considered as 100%.
Direct sequencing of amplicons
In order to validate the results of ARMS amplification, direct sequencing was performed on amplicons generated in individual PCR reactions that contained different primer combinations expected to generate either the wild-type (primers FI-1 þ RO-1) or the V617F mutated cDNA (primers FO-1 þ RI-1) (Figure 1a ). PCR products, purified with the QIAquick PCR purification kit, were sequenced directly from both strands with either forward or reverse primer, using the BigDye terminator system and the ABI 310 analyzer (Applied Biosystem).
Real-time quantitative PCR for PRV-1 and NF-E2 expression levels
Neutrophil PRV-1 expression levels were quantified as described by Klippel et al. 27 using the Taqman one-step procedure and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as the housekeeping gene, by means of ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). The PRV-1 cyle threshold (C T ) ratio was calculated from the mean value of triplicate PRV-1 C T determinations divided by the mean GAPDH C Ts ; the PRV-1 C T ratio in healthy blood donors (n ¼ 30) was 1.3770.09. 28 Neutrophil NF-E2 expression levels were determined with the TaqMan Gene Expression Assay (Hs00232351_m1, Applied Biosystems), in quadruplicate. NF-E2 gene expression was calculated according to the comparative C T method of relative quantitation versus GAPDH. To normalize data, DDC T was calculated for each sample using the mean of its DC T values subtracted of the mean DC T value measured in a population of 30 healthy subjects, considered as a calibrator; relative quantitation (RQ) value was expressed as 2
ÀDDCT .
Statistical analysis
Data were computed using the GraphPad InStat software (GraphPad Software, San Diego, CA, USA); the chosen level of significance from two-sided tests was Po0.05.
Results and discussion
The aim of this study was to develop a quantitative methodology for the assessment of mutated JAK2 in MPD as a tool to prospectively evaluate the clinical impact of the mutation in these disorders. ARMS-PCR is an efficient amplification procedure originally developed for the analysis of SNP in genomic samples, 26 and has already been employed for the analysis of JAK2 mutation in MPD starting from granulocyte DNA. 10 We have adopted this methodology to devise an assay suitable for the relative quantitation of JAK2 wild-type and V617F mutated RNAs in samples of granulocytes obtained from patients with the Ph 0 -negative MPD (Figure 1a and b) . Capillary electrophoresis was used to resolve the two amplicons of 224 and 199 bp, analysis on granulocyte cDNA; patients were firstly typed according to the allele-specific (ASO) technique and restriction enzyme analysis on genomic DNA to evaluate the presence of JAK2 V617F mutation and the heterozygote/homozygote status. Pt #1 is a JAK2 wild-type (WT) patient; Pt #2 is a JAK2 V617F heterozygote patient, whereas Pt #3 and Pt #4 are two JAK2 V617F homozygote patients; the % of mutated cDNA over total is shown on the right. Quantitative assay for JAK2 V617F RNA AM Vannucchi et al corresponding to the wild-type and V617F mutated allele, respectively, flanked by fluorescently labelled, mutation-specific primers ( Figure 1b and c) ; the peak area ratio of the two amplicons was then calculated (Figure 2a) . Direct sequencing analysis on gel-isolated amplicons confirmed that they had the expected sequence of wild-type and mutated fragment, respectively (Figure 1c) . Furthermore, in 40 healthy subjects, only the wild-type cDNA could be amplified, whereas in the HEL cell line, known to be homozygote 7 for JAK2
V617F
, only the mutated amplicon was detectable; these observations indicate that the two primer sets are specific in their target sequence. In preliminary experiments using different PCR cycles, a constant ratio value between the two amplicons was maintained in the range of 22-30 cycles (not shown in detail), and a limit PCR cycle of 27 was used in all further experiments to avoid saturation possibly occurring at higher PCR cycle number. Dilution experiments, in which the cDNAs from a normal subject and a homozygote patient showing 100% of the mutated allele (Pt #1 and Pt #4, respectively, in Figure 2a) were mixed in varying proportions, demonstrated that the assay has a nice performance (r ¼ 0.98), with a detection limit for mutated cDNA of D1% ( Figure 2b) ; furthermore, the assay is linear with respect to the amount of cDNA in the range of 12.5-75 ng (Figure 2c ). The intra-assay and inter-assay values of the ARMS assay were 4% (n. of experiments ¼ 6; range ¼ 1-6%) and 7% (n. of experiments ¼ 15; range ¼ 3-11%), respectively. Finally, to test whether the JAK2 mRNA was stable over time, the ratios of mutated versus wild-type alleles were evaluated in samples that had been processed soon after collection (initial value) and at 6, 24 and 36 h at room temperature. In six MPD patients, who showed initial mutated allele values ranging from 6 to 87%, the variability of the allele ratio at different times was 572%, to suggest that the stability of either wild-type or mutated JAK2 mRNA is substantially comparable and mantained within this time limit (data not shown in detail); this observation has implications in the clinical practice, where samples may not be processed immediately.
By using this novel assay, we evaluated a population of 179 MPD subjects who were comparatively analyzed with the ASO-PCR assay for genotyping the JAK2 V617F mutation and with the ARMS assay for evaluating the mutated JAK2 RNA levels ( Table 1) . We found that the percentage of patients displaying the JAK2 V617F mutation was higher with the ARMS assay than with the genomic technique, as the proportion of mutated patients rose from 65 to 74%; therefore, the ARMS assay allowed to identify a 9% more JAK2 V617F patients, who actually presented low levels of JAK2 mutated RNA in the range of 1-4%. We also evaluated 20 subjects with reactive erythrocytosis, who were JAK2 wild type according to the ASO-PCR assay and who even with the more sensitive ARMS assay did not present mutated JAK2 RNA. Therefore, the ARMS assay seems to offer greater sensitivity but comparable specificity in the diagnostic approach to MPD patients as compared to the 'standard' ASO-PCR assay. Furthermore, by using the ARMS procedure on granulocyte DNA, as originally decribed by Jones and coworkers, 10 we failed to demonstrate the mutation in five of 16 patients who presented low levels of mutated JAK2 RNA (in the range of 1-6%), to furtherly indicate that the assay based on cDNA amplification has improved sensitivity (not presented in detail).
Of the 116 JAK2 V617F patients examined, 88 (76%) were heterozygotes and 28 (24%) homozygotes, according to the results of BsaXI restriction enzyme analysis on genomic DNA ( Table 2) . By using the ARMS assay, we found a discrete distribution of the percentage of mutated JAK2 RNA, between 1 and 51% (mean 28.4%) in heterozygotes and between 45 and 100% in homozygotes (mean 69.4%) ( Table 2) ; the difference between the two groups of patients was statistically significant (P ¼ 0.01). Also, heterozygote ET patients showed significantly lower JAK2 mutated RNA levels as compared to either PV or IM heterozygote patients (P ¼ 0.02 and P ¼ 0.03, respectively).
The quantitation of mutated JAK2 RNA is expected to provide useful information in the clinical context of MPD; indeed, it seems likely that the phenotype of different MPD entities reflects both the mutated gene dosage and the residual amount of normal JAK2 allele. 19 In fact, normal JAK2 is capable of downmodulating STAT5 activation induced by the mutated 6 in a cell line that had acquired cytokine independence following transfection of JAK2 V617F . Accordingly, we observed that the actual percentage of mutated JAK2 RNA correlated with increased expression levels of both PRV-1 and NF-E2 genes in the granulocytes of the entire population of MPD patients, although some differences were noted among the unique clinical entities (Figure 3) . In fact, a significant correlation between mutated JAK2 and PRV-1 and/or NF-E2 RNA levels was found in patients with PV and IM, unlike in ET; also, Campbell et al. 19 found no difference in PRV-1 levels between JAK2 mutated and wild-type ET patients, as we also reported. 22 In summary, the ARMS technique described herein seems to have some advantages over available genomic techniques owing to a greater sensitivity, but most importantly because it provides a reliable estimate of the levels of wild-type and mutated JAK2 mRNA. The potential clinical impact of this novel approach is supported by the observation that the abnormal expression of two disease-related genes, PRV-1 and NF-E2, was dose-dependent with the levels of mutated JAK2 RNA in granulocytes. Overall, we believe that the ARMS assay may be more appropriate in the search for clinical correlates than the simpler classification of JAK2 mutated patients into heterozygotes or homozygotes, as currently defined by genomic-based techniques. NF -E2 RQ Figure 3 The proportion of JAK2 V617F mRNA, as assessed by the amplification-refractory mutation sequencing (ARMS) assay, correlates with increased levels of both PRV-1 (a) and NF-E2 (b) gene expression levels in granulocytes. In panel a, lower PRV-1/GAPDH ratios indicate higher expression levels of the gene; RQ, relative quantity. Plots shown on the left side are representative of all patients examined (n ¼ 93 for PRV-1 and n ¼ 89 for NF-E2), whereas panels on the right side show results obtained in individual diseases.
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